Hutchmed (China) Limited

Share Issue/Capital Change • May 8, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6045G

Hutchison China Meditech Limited

08 May 2014

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Results of Annual General Meeting

London: Thursday, 8 May 2014:Chi-Med today announces that all ordinary resolutions and special resolution put to its Annual General Meeting ("AGM") held on 8 May 2014 were duly passed.  The poll results of the resolutions were as follows:

		Number of Votes (%)*
Ordinary Resolutions		For	Against	Withheld#
1	To consider and adopt the statement of audited accounts and the reports of the directors and independent auditor for the year ended 31 December 2013.	45,105,584 (99.8914%)	49,030 (0.1086%)	200
2(a)	To re-elect Mr Johnny Cheng as a director.	45,108,659 (99.8978%)	46,155 (0.1022%)	0
2(b)	To re-elect Professor Christopher Huang as a director.	45,154,814 (100%)	0 (0%)	0
2(c)	To re-elect Mr Christopher Nash as a director.	45,154,614 (100%)	0 (0%)	200
3	To re-appoint PricewaterhouseCoopers as the auditor of Chi-Med and authorise the board of directors to fix the auditor's remuneration.	45,154,614 (99.9996%)	200 (0.0004%)	0
4(a)	Item 4(A) of the notice of the AGM (To grant a general mandate to the directors of Chi-Med to issue additional shares)	43,921,319 (98.8222%)	523,465 (1.1778%)	710,030
Special Resolution
4(b)	Item 4(B) of the notice of the AGM (To disapply pre-emption rights)	42,099,014 (93.2326%)	3,055,800 (6.7674%)	0
Ordinary Resolution
4(c)	Item 4(C) of the notice of the AGM (To grant a general mandate to the directors of Chi-Med to repurchase shares of Chi-Med)	45,102,614 (99.8848%)	52,000 (0.1152%)	200

*  Percentages rounded to 4 decimal places

A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and againsta resolution.

As at the date of the AGM, the number of issued shares of Chi-Med was 52,051,448, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolution proposed at the AGM. 

Ends

Enquiries

Chi-Med Christian Hogg, CEO	Telephone:     +852 2121 8200
Panmure Gordon (UK) Limited Richard Gray Andrew Potts	Telephone:     +44 20 7886 2500
Citigate Dewe Rogerson Anthony Carlisle David Dible	Telephone:     +44 20 7638 9571 Mobile:             +44 7973 611 888 Mobile:             +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med (LSE: HCM) is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK: 13).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGSSDFSAFLSEII